Caroline Dive

Cancer Research UK

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index97

i10-index323

Publications944

Citations46,388

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 99

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK
EClinicalMedicine · 2026-06-01
Table S5 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Table S3 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Figure 2 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Table S4 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Figure 1 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Figure 7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Table S8 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Table S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Figure 3 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Table S6 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Supplementary Figures S1-S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Table S2 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Figure 4 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Table S1 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Supplementary Methods 1 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Figure 5 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Figure 6 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Data from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026-06-01
Advancing the applications of liquid biopsies in oncology
Nature Reviews Genetics · 2026-05-29

Open author page on OpenAlex →